Skip to main content

Chasing Genzyme, AvroBio bags $60M to fund Fabry disease gene therapy trial

The 30-employee company said Thursday that it had raised $60 million in new financing to help fund a mid-stage trial of an experimental gene therapy for Fabry disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.